Inc.;H. Lee Moffitt Cancer Center and Research Institute
发明人:
Marco L. DAVILA
申请号：
US16632086
公开号：
US20200165348A1
申请日:
2018.07.18
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Disclosed are compositions and methods for targeted treatment of CD123-expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill CD123-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a CD123-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
